WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

REPORT: See what’s under construction in U.S. shipyards — download the 2025 Construction Survey. → Click Here

Workboat Indexes

My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.52 +0.01 (+0.04%)
Streaming Delayed Price Updated: 10:02 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 195,657
Open 27.23
Bid (Size) 27.47 (2)
Ask (Size) 27.55 (2)
Prev. Close 27.51
Today's Range 26.95 - 27.64
52wk Range 12.91 - 28.69
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
Novartis Strengthens Kidney Disease Pipeline With Promising Data
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga

Performance

YTD
+45.1%
+45.1%
1 Month
+20.9%
+20.9%
3 Month
+66.7%
+66.7%
6 Month
+84.5%
+84.5%
1 Year
+52.5%
+52.5%

More News

Read More
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup
Via Chartmill
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Shares Are Trading Higher Wednesday: What's Going On?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High
Via Investor's Business Daily
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application
Via Stocktwits
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
From Travere Therapeutics, Inc.
Via Business Wire
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
Via Benzinga
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch
Via Investor's Business Daily
Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss
Via Chartmill
Travere Therapeutics Reports Second Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?
Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
What is the current price of Travere Therapeutics, Inc. - Common Stock?
The current price of Travere Therapeutics, Inc. - Common Stock is 27.52
When was Travere Therapeutics, Inc. - Common Stock last traded?
The last trade of Travere Therapeutics, Inc. - Common Stock was at 10/17/25 10:02 AM ET
What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.67B
How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.